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DITORIAL
o  more  hic  sunt  dracones:  Portugal  is  in the COPD  mapem  mais  hic  sunt  dracones:  Portugal  encontra-se  no  mapa  da  DPOC
t
t
n
t
v
c
P
t
o
a
t
s
n
i
E
m
i
d
a
(
i
o
n
r
l
i
c
p
L
s
ﬁceanic  explorers  used  to  denote  dangerous  or  unexplored
erritories  with  the  Latin  quote  ‘‘Hic  sunt  dracones’’,  that
s  ‘‘Here  be  dragons’’,  in  imitation  of  the  medieval  practice
f  putting  dragons,  sea  serpents  and  other  mythological
reatures  into  uncharted  areas  of  maps.  We  do  not  know
hether  Fernão  de  Magalhães  (1480--1521)  and  his  acolytes
ver  smoked,  and  it  is  very  unlikely  that  he  ever  performed
ny  archaic  lung  function  testing,  but  now  the  analogy  would
o  longer  pertain  to  COPD  in  Portugal.  This  is  why  the  ﬁrst
urden  of  Lung  Disease  (BOLD)  study  report  in  Portugal  is  so
elcome.1
The  European  Community  Respiratory  Health  Survey
ECRHS),2 initially  studied  the  prevalence  of  asthma  in  young
dults,  and  then  the  International  Study  of  Asthma  and  Aller-
ies  in  Children  (ISAAC)  analyzed  the  child  population,3 and
he  Portuguese  participation  provided  valuable  data  widely
sed  elsewhere.4--7 In  the  very  same  way  BOLD  has  aimed  to
btain  population  prevalence  data  of  COPD  using  standard-
zed  spirometry  and  deﬁnitions.  From  its  onset  in  2004,8 and
p  to  December  2012,  BOLD  was  completed  in  23  centres
orldwide,  and  another  six  sites  are  expected  to  complete
ata  collection  in  2013.
The  highly  cited,  inﬂuential  Global  Burden  of  Disease
GBD)  studies  estimated  that  COPD  causes  the  death  of
t  least  2.9  million  people  annually.  Estimates  of  COPD  as
ixth  in  the  global  mortality  ranking  in  1990,9 were  revised
pwards  to  fourth  in  2006  and  were  projected  to  be  the
hird  by  2020.10 To  many  people’s  surprise,  a  GBD  2010
ew  update,  which  has  just  been  released,  identiﬁed  some
ortality  trends  were  declining.11 So,  from  all  the  non-
ommunicable  diseases  (NCDs)  at  a  global  level,  only  COPD
nd  congenital  anomalies  have  declined,  yet  chronic  respira-
ory  diseases  as  a  group  accounted  for  4.7%  of  global  DALYs,
ith  COPD  making  up  two-thirds  of  the  total  and  asthma
early  a  ﬁfth  of  the  total.12 Data  from  Barbara  et  al.1 are
xpected  to  be  included  in  any  new  GBD  update.
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hat  there  were  very  little  previous  data  on  COPD  in  Por-
ugal;  they  had  been  minimally  represented  by  a  small
on-comparative  study,  which  only  had  pre-BD  spirome-
ry  data,  from  2002.13 Now,  using  data  with  the  highest
alidity,  clinicians,  investigators  and  health  administrators
an  start  quoting  ﬁgures  about  the  prevalence  of  COPD  in
ortugal;  it  is  14.2%,  18.7%  in  men  and  10.5%  in  women,  and
he  vast  majority  (86.8%)  is  as  yet  undiagnosed.  Using  back
f  an  envelope  calculations,  one  can  extrapolate  that  from
 total  population  of  10.5  million,  among  5.4  million  Por-
uguese  adults  aged  40  years  and  older,14 at  least  750,000
uffer  from  COPD,  and  more  than  660,000  are  still  undiag-
osed.
These  estimates,  using  the  COPD  GOLD  ﬁxed  ratio  def-
nition  of  post-BD  FEV1/FVC  <  0.70,  place  Portugal  in  the
uropean  average.  COPD  in  Portugal  is  more  frequent  in
en,  and  it  increases  with  age,  and  with  more  smok-
ng  exposure.  These  very  basic,  conﬁrmatory  estimates  of
escriptive  epidemiology  have  been  long  awaited.  As  well
s  its  novelty  factor,  the  use  of  a random  digit  dialling
RDD)  telephone  sampling  to  screen  for  potential  responders
s  innovative  and  appropriate.  However,  critical  appraisal
f  limitations  include  the  27%  response  rate,  although  the
on-response  study  seems  reassuring  in  relation  to  the  ﬁnal
epresentativity  of  the  obtained  sample  to  the  general  popu-
ation,  with  no  differences  in  responders  vs.  non-responders
n  terms  of  age,  smoking,  previous  respiratory  diseases,  or
omorbidities;  only  for  gender.  Overall,  the  20.2%  crude
revalence  was  downgraded  to  14.2%.  Data  only  relates  to
isbon,  while  high  heterogeneity  is  seen  in  other  national
tudies  with  multiple  centres  and  areas.15,16 Given  that  the
eldwork  was  carried  out  in  2008,  an  update  will  be  deemed
ecessary  in  due  course.  Of  interest  are  the  high  frequency
f  airﬂow  limitation  in  never-smokers,  to  exploring  other
entres  within  the  Portuguese  geography,  and  local  deter-
inants  of  COPD  in  women,17 all  are  potential  avenues  for
uture  research.
Monitoring  epidemiological  trends  is  an  arduous,  lengthy
ndertaking.  With  an  estimated  210  million  people
gia.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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worldwide  suffering  from  COPD,  but  with  80%  or  higher
yet  undiagnosed,  there  remain  many  large  areas  in  the
Globe  with  blank  data  regarding  spirometry-based  COPD
estimates.
Since  you  cannot  manage  what  you  do  not  measure,  the
ﬁrst  step  to  counter  any  major  health  problem  is  to  mea-
sure  its  burden.  This  very  basic,  fundamental  Public  Health
principle  applies  well  to  COPD.  Thanks  to  Barbara  et  al.,1
Portugal  is  no  longer  a  blank  spot  in  the  COPD  map.
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